On November 21, 2022 AskGene Pharma Inc. reported the submission of an Investigational New Drug (IND) application for ASKG915 to the United States Food and Drug Administration (FDA) (Press release, AskGene Pharmaceuticals, NOV 21, 2022, View Source [SID1234624281]). ASKG915 is a recombinant human anti-PD-1 monoclonal antibody and IL-15 prodrug fusion protein for oncology indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jian-Feng (Jeff) Lu, Ph.D., CEO of AskGene commented: "ASKG915 is our third cytokine prodrug entering clinical development, which was discovered and developed using our propriety SmartKine cytokine platform technology. Based on the projected dose, it will have full bifunction activities encompassing the combined therapeutic potencies of IL-15 super-agonist and Anti-PD1. ASKG915 is the first anti-PD-1-IL-15 prodrug fusion molecule moving into clinical development. It represents the next generation of immunotherapy and is expected to achieve better safety, efficacy, and overall benefit for patients, especially those who may not respond to current immunotherapies."

On November 21, 2022 PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, reported two executives will be giving presentations at the World Vaccine & Immunotherapy Congress, which will take place from November 28 through December 1, 2022, in San Diego (Press release, PDS Biotechnology, NOV 21, 2022, View Source [SID1234624280]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Development of a universal flu vaccine based on the InfectimuneTM platform

More than 800 attendees are expected to attend the World Vaccine & Immunotherapy Congress to examine challenges around scientific, commercial, public health and policy issues in manufacturing, clinical trials, regulation, immune profiling, biomarkers, platform technologies, and additional topics.

"We welcome the opportunity to highlight the Versamune and Infectimune platforms and their potential to address significant unmet medical needs to the biotechnology and scientific community," said Dr. Frank Bedu-Addo, PDS Biotech President and CEO. "We are looking forward to advancing our product development in both oncology and infectious disease, ultimately to improve patient care."

About Versamune

Current immunotherapies have demonstrated an ability to treat certain cancers, but limitations with their effectiveness persist. Versamune is a novel investigational T cell activating platform designed to stimulate a precise immune system response to cancer-specific proteins. PDS Biotech is advancing multiple Versamune based clinical and pre-clinical programs with its lead clinical candidate – PDS0101 – targeting HPV-positive cancers.

About InfectimuneTM

Infectimune is a novel proprietary investigational T cell immune activating platform technology designed to train the immune system to better protect against disease. The Infectimune platform stimulates the immune system to recognize the pathogen and induce potent killer T cell and memory T cell response for long-term protection safely with no clinically relevant toxicities.

On November 21, 2022 Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, reported that company management will participate in a fireside chat on Thursday, December 1, 2022 at 10:05 AM ET at the Evercore ISI 5th Annual HealthCONX Conference (Press release, Heron Therapeutics, NOV 21, 2022, View Source [SID1234624279]). The conference is being held in a virtual format, November 29-December 1, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available on the Company’s website at www.herontx.com in the Investor Resources section.

On November 21, 2022 UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, reported that it will participate in a virtual fireside chat at the upcoming Evercore ISI 5th Annual HealthCONx Conference on November 29, 2022 at 3:55 PM ET (Press release, UroGen Pharma, NOV 21, 2022, https://investors.urogen.com/news-releases/news-release-details/urogen-pharma-present-evercore-isi-5th-annual-virtual-healthconx [SID1234624278]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be available in the "Events and Presentations" section of UroGen’s investor website. A replay will be available for approximately 30 days.

On November 21, 2022 Novo Nordisk reported that initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules") (Press release, Novo Nordisk, NOV 21, 2022, View Source [SID1234624277]). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12- month period beginning 2 February 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period from 7 November 2022 to 30 January 2023.

With the transactions stated above, Novo Nordisk owns a total of 28,282,803 B shares of DKK 0.20 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12- month period beginning 2 February 2022. As of 18 November 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 26,593,617 B shares at an average share price of DKK 785.54 per B share equal to a transaction value of DKK 20,890,241,156.